ImmuCell Corporation Total Assets
ImmuCell Corporation total assets. Based on the latest financial reports, ImmuCell Corporation (ICCC) holds total assets worth $46.63 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ICCC market cap overview for the company's overall valuation and market capitalisation.
Total Assets of ImmuCell Corporation (1989–2025)
Total assets of ImmuCell Corporation from 1989 to 2025. This chart illustrates how ImmuCell Corporation's total assets have evolved over time, based on quarterly financial data. See ICCC share price today for real-time trading data and today's change.
ImmuCell Corporation - Asset Composition Analysis
ImmuCell Corporation Total Assets Breakdown (December 2025)
ImmuCell Corporation total assets breakdown as of December 2025. ImmuCell Corporation's total assets of $46.63 Million consist of 39.8% current assets and 60.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.0% |
| Accounts Receivable | $3.42 Million | 8.0% |
| Inventory | $9.27 Million | 21.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $95.56K | 0.2% |
Asset Composition Trend (1989–2025)
This chart illustrates how ImmuCell Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of ImmuCell Corporation to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ImmuCell Corporation's current assets represent 39.8% of total assets in 2025, a decrease from 90.0% in 1989.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2025, down from 15.0% in 1989.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 1989.
- Asset Diversification: The largest asset category is inventory at 21.8% of total assets.
ImmuCell Corporation Competitors by Total Assets
Key competitors of ImmuCell Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ImmuCell Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.75 | 3.85 | 7.64 |
| Quick Ratio | 2.71 | 1.99 | 6.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.64 Million | $12.69 Million | $13.50 Million |
ImmuCell Corporation - Advanced Valuation Insights
This section examines the relationship between ImmuCell Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.87 |
| Latest Market Cap to Assets Ratio | 2.08 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | $42.53 Million |
| Market Capitalization | $88.55 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ImmuCell Corporation's assets at a significant premium (2.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: ImmuCell Corporation's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ImmuCell Corporation (1989–2025)
The table below shows the annual total assets of ImmuCell Corporation from 1989 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $42.53 Million | -5.70% |
| 2024-12-31 | $45.10 Million | +2.95% |
| 2023-12-31 | $43.81 Million | -2.35% |
| 2022-12-31 | $44.86 Million | +0.89% |
| 2021-12-31 | $44.47 Million | +10.20% |
| 2020-12-31 | $40.35 Million | +4.29% |
| 2019-12-31 | $38.69 Million | +18.21% |
| 2018-12-31 | $32.73 Million | -4.57% |
| 2017-12-31 | $34.30 Million | +38.88% |
| 2016-12-31 | $24.70 Million | +69.15% |
| 2015-12-31 | $14.60 Million | +32.11% |
| 2014-12-31 | $11.05 Million | +0.83% |
| 2013-12-31 | $10.96 Million | -0.63% |
| 2012-12-31 | $11.03 Million | +0.36% |
| 2011-12-31 | $10.99 Million | +2.23% |
| 2010-12-31 | $10.75 Million | +7.68% |
| 2009-12-31 | $9.98 Million | -1.42% |
| 2008-12-31 | $10.13 Million | -2.73% |
| 2007-12-31 | $10.41 Million | -8.37% |
| 2006-12-31 | $11.36 Million | +14.15% |
| 2005-12-31 | $9.96 Million | +4.47% |
| 2004-12-31 | $9.53 Million | +16.41% |
| 2003-12-31 | $8.19 Million | +8.96% |
| 2002-12-31 | $7.51 Million | +5.57% |
| 2001-12-31 | $7.12 Million | +10.45% |
| 2000-12-31 | $6.44 Million | +67.11% |
| 1999-12-31 | $3.86 Million | +24.39% |
| 1998-12-31 | $3.10 Million | -3.13% |
| 1997-12-31 | $3.20 Million | +3.23% |
| 1996-12-31 | $3.10 Million | -3.13% |
| 1995-12-31 | $3.20 Million | +3.23% |
| 1994-12-31 | $3.10 Million | 0.00% |
| 1993-12-31 | $3.10 Million | +34.78% |
| 1992-12-31 | $2.30 Million | +4.55% |
| 1991-12-31 | $2.20 Million | -35.29% |
| 1990-12-31 | $3.40 Million | -15.00% |
| 1989-12-31 | $4.00 Million | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more